Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Linagliptin And Metformin Hydrochloride
Brand Name
Linagliptin And Metformin Hydrochloride
Generic Name
Linagliptin And Metformin Hydrochloride
Active Ingredient
LinagliptinCategory
Dipeptidyl Peptidase 4 Inhibitor [EPC]
Variants
3
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Linagliptin And Metformin Hydrochloride, you must consult a qualified healthcare professional.
Detailed information about Linagliptin And Metformin Hydrochloride
Linagliptin is a prescription medication used to improve blood sugar control in adults with type 2 diabetes mellitus. As a Dipeptidyl Peptidase 4 (DPP-4) inhibitor, it works by increasing the levels of natural substances that lower blood sugar when it is high.
The standard recommended dose for linagliptin (Tradjenta) in adults with type 2 diabetes mellitus is 5 mg taken once daily. This dose is consistent whether the medication is used as monotherapy or in combination with other glucose-lowering agents. Because linagliptin has a long terminal half-life, it provides sustained DPP-4 inhibition over a 24-hour period, allowing for convenient once-daily dosing.
In clinical practice, if linagliptin is added to a regimen containing insulin or an insulin secretagogue (such as a sulfonylurea), your healthcare provider may consider lowering the dose of the insulin or sulfonylurea to reduce the risk of hypoglycemia (low blood sugar).
The safety and effectiveness of linagliptin in pediatric patients (under the age of 18) have not been established. Clinical trials are ongoing to evaluate its use in children with type 2 diabetes, but currently, it is not FDA-approved for use in this population. Parents should consult a pediatric endocrinologist for appropriate treatment options for childhood diabetes.
One of the primary advantages of linagliptin is that no dosage adjustment is required for patients with renal impairment. This includes patients with mild, moderate, or severe renal insufficiency, as well as those with End-Stage Renal Disease (ESRD) requiring hemodialysis or peritoneal dialysis. Because only a tiny fraction of the drug is cleared by the kidneys, the plasma concentration remains stable even when kidney function declines.
No dosage adjustment is necessary for patients with mild, moderate, or severe hepatic (liver) impairment. Clinical studies have shown that liver dysfunction does not significantly alter the pharmacokinetics of linagliptin.
No dosage adjustment is required based solely on age. However, because older adults are more likely to have decreased renal function and multiple comorbidities, healthcare providers should monitor this population closely for overall treatment response and potential side effects.
To ensure the maximum benefit and safety of linagliptin, follow these instructions:
If you miss a dose of linagliptin, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects.
In the event of an overdose, contact your local poison control center or seek emergency medical attention immediately. While linagliptin has a low risk of causing hypoglycemia on its own, a massive overdose could potentially lead to complications. Symptoms of a significant overdose may include severe nausea, vomiting, or abdominal discomfort. Treatment is generally supportive, focusing on removing any unabsorbed drug from the gastrointestinal tract and monitoring clinical status.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could lead to a dangerous rise in your blood sugar levels.
Linagliptin is generally well-tolerated by most patients. The most frequently reported side effects, which may affect more than 10% of users in some clinical settings (particularly when combined with other drugs), include:
Linagliptin is a potent medication that requires careful monitoring. It is specifically intended for Type 2 Diabetes and should not be used to treat Type 1 Diabetes or Diabetic Ketoacidosis (a serious condition involving high ketones in the blood). Before starting this medication, ensure your healthcare provider is aware of your full medical history, particularly any history of pancreatic disease, gallstones, or heart failure.
As of 2026, there are no FDA black box warnings for Linagliptin. It is considered to have a favorable safety profile compared to many other classes of antidiabetic medications.
There have been post-marketing reports of acute pancreatitis in patients taking linagliptin. If pancreatitis is suspected, the medication should be discontinued promptly. It is unknown whether patients with a prior history of pancreatitis are at an increased risk while taking linagliptin, but caution is advised.
There are no drugs that are strictly contraindicated (forbidden) for use with linagliptin. However, certain combinations are highly discouraged because they significantly neutralize the drug's effectiveness.
Linagliptin must NEVER be used in the following circumstances:
Linagliptin is classified under the historical FDA Pregnancy Category B. This means that animal reproduction studies (in rats and rabbits) have failed to demonstrate a risk to the fetus, even at doses much higher than the human therapeutic dose. However, there are no adequate and well-controlled studies in pregnant women.
Because maintaining stable blood glucose is critical during pregnancy to prevent birth defects and maternal complications, healthcare providers usually prefer better-studied medications like insulin. Linagliptin should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. If you become pregnant while taking linagliptin, notify your doctor immediately.
It is not known whether linagliptin is excreted in human milk. Animal studies have shown that linagliptin is secreted in the milk of lactating rats. Because many drugs are excreted in human milk and there is a potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Linagliptin is a competitive and reversible inhibitor of the enzyme Dipeptidyl Peptidase 4 (DPP-4). This enzyme is responsible for the rapid degradation of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By inhibiting DPP-4, linagliptin increases the 'half-life' of these hormones. This results in higher levels of active incretins, which stimulate the pancreas to produce more insulin and signal the liver to stop producing excess glucose. Crucially, this effect is glucose-dependent, meaning it only occurs when blood sugar levels are elevated, which minimizes the risk of hypoglycemia.
Linagliptin binds very tightly to the DPP-4 enzyme. A 5 mg dose inhibits more than 80% of DPP-4 activity for over 24 hours. This high affinity and slow dissociation rate allow for consistent blood sugar control with once-daily dosing. It reduces both fasting plasma glucose (FPG) and post-meal (postprandial) glucose levels. It also reduces HbA1c levels by approximately 0.5% to 0.7% on average when used as monotherapy.
| Parameter | Value |
Common questions about Linagliptin And Metformin Hydrochloride
Linagliptin is primarily used to improve blood sugar control in adults with type 2 diabetes mellitus. It works by increasing the levels of natural incretin hormones in the body, which help the pancreas release insulin more effectively. It is typically used alongside a healthy diet and regular exercise program. Doctors may prescribe it as a single medication or in combination with other drugs like metformin or insulin. It is not intended for use in patients with type 1 diabetes or for treating diabetic ketoacidosis.
The most common side effects reported by patients taking linagliptin include cold-like symptoms such as a runny nose, sore throat, and cough. Some patients may also experience a mild headache or diarrhea. Unlike many other diabetes medications, linagliptin is weight-neutral and does not typically cause weight gain. While these common side effects are usually mild, it is important to monitor how you feel and report any persistent or worsening symptoms to your healthcare provider. Rare but serious side effects like pancreatitis or severe joint pain require immediate medical attention.
You should use caution when consuming alcohol while taking linagliptin. Alcohol can interfere with blood sugar control, potentially leading to either very high or very low blood sugar levels depending on the amount consumed and whether you have eaten. Furthermore, excessive alcohol consumption is a significant risk factor for pancreatitis, which is a rare but serious side effect associated with linagliptin. It is best to discuss your alcohol intake with your doctor to determine what is safe for your specific health situation. Always avoid 'binge drinking' while on diabetes medication.
Linagliptin is generally not the first choice for managing diabetes during pregnancy. While animal studies have not shown direct harm to the fetus, there is a lack of comprehensive data regarding its safety in pregnant women. Most clinical guidelines recommend using insulin to manage blood sugar during pregnancy because its effects are well-understood and it does not cross the placenta in significant amounts. If you are planning to become pregnant or find out you are pregnant while taking linagliptin, you should contact your healthcare provider immediately to discuss a safer treatment plan. Managing blood sugar is vital for a healthy pregnancy.
Linagliptin begins to inhibit the DPP-4 enzyme within about 90 minutes of taking the first dose, but it may take several weeks to see the full effect on your blood sugar levels. Most patients will notice a decrease in their daily blood glucose readings within the first week or two. However, the impact on your HbA1c—which measures your average blood sugar over three months—will not be fully evident until you have been on the medication for at least 8 to 12 weeks. Consistency is key, so you should continue taking the medication even if you do not feel an immediate change. Your doctor will use lab tests to confirm the drug's effectiveness.
You should not stop taking linagliptin suddenly without first consulting your healthcare provider. Stopping the medication abruptly can cause your blood sugar levels to rise significantly, which may increase the risk of long-term diabetes complications like nerve damage or kidney issues. If you need to stop the medication due to side effects or a change in your treatment plan, your doctor will likely recommend a different medication to ensure your blood sugar remains controlled. Always discuss any concerns about your medication with a medical professional before making changes to your regimen. There is no 'withdrawal' effect, but the loss of glucose control is a serious concern.
If you miss a dose of linagliptin, you should take it as soon as you remember. If it is almost time for your next dose, simply skip the missed dose and take your next one at the regularly scheduled time. You should never take two doses at once to 'catch up,' as this can increase the risk of side effects. To help prevent missed doses, try taking your medication at the same time every day, perhaps with a specific daily habit like brushing your teeth. If you frequently forget your doses, consider using a pill organizer or a smartphone reminder app.
No, linagliptin is considered a 'weight-neutral' medication, meaning it does not typically cause weight gain or weight loss. This is a significant advantage over other diabetes medications like sulfonylureas, thiazolidinediones, or insulin, which are often associated with weight gain. Because managing weight is a crucial part of treating type 2 diabetes, linagliptin is often a preferred choice for patients who are concerned about their weight. However, it is still important to maintain a healthy diet and exercise routine while taking this medication. If you notice sudden or unusual weight gain, it could be a sign of heart failure and should be reported to your doctor.
Yes, linagliptin is frequently taken in combination with other diabetes medications such as metformin, SGLT2 inhibitors, or insulin. However, some drugs can interact with linagliptin. For example, the antibiotic rifampin can make linagliptin less effective, and taking it with insulin can increase the risk of low blood sugar. It is essential to provide your doctor and pharmacist with a complete list of all the medicines, supplements, and herbal products you use. This allows them to check for potential interactions and adjust your dosages if necessary to ensure your safety and the effectiveness of your treatment.
As of 2026, generic versions of linagliptin have become available in many markets following the expiration of the original patents for Tradjenta. Generic linagliptin contains the same active ingredient and meets the same quality and safety standards as the brand-name version. Using the generic form can significantly reduce the cost of your treatment. You should check with your pharmacist or insurance provider to see if a generic version is covered under your plan. Regardless of whether you take the brand-name or generic version, the dosage and instructions for use remain the same.
Other drugs with the same active ingredient (Linagliptin)
> Warning: Stop taking Linagliptin and call your doctor immediately if you experience any of the following serious symptoms:
Long-term use of linagliptin is generally considered safe based on cardiovascular outcome trials (CVOTs) like CARMELINA, which followed patients for several years. There is no evidence that linagliptin increases the risk of cancer or long-term organ damage. However, patients should remain vigilant for the development of chronic joint pain or skin changes over time.
No FDA black box warnings currently exist for Linagliptin. However, the FDA has issued safety communications regarding the risks of heart failure and severe joint pain for the entire DPP-4 inhibitor class, which includes linagliptin. Patients with pre-existing heart or kidney disease should be monitored more closely.
Report any unusual symptoms or persistent side effects to your healthcare provider. Monitoring your blood sugar regularly will help you and your doctor determine how well the medication is working and if any side effects are related to fluctuations in glucose levels.
An association between DPP-4 inhibitor use and heart failure has been observed in some clinical trials of other drugs in this class (notably saxagliptin). While the CARMELINA trial for linagliptin did not show a statistically significant increase in heart failure hospitalizations, the FDA still advises caution. Patients with a history of heart failure or renal impairment should be monitored for signs and symptoms of heart failure during therapy.
In 2015, the FDA added a warning about the risk of severe and disabling joint pain associated with DPP-4 inhibitors. The onset of symptoms can range from one day to years after initiation. Discontinuation of the drug usually results in the resolution of symptoms.
When linagliptin is used in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin, the risk of hypoglycemia is significantly increased. A reduction in the dose of the insulin secretagogue or insulin may be necessary to mitigate this risk.
To ensure linagliptin is working effectively and safely, the following monitoring is typically recommended:
Linagliptin itself does not typically cause drowsiness or impaired coordination. However, if used with other diabetes medications that cause hypoglycemia, your ability to drive or operate machinery may be compromised. Always ensure your blood sugar is stable before performing these tasks.
Alcohol can affect blood sugar levels and increase the risk of both hypoglycemia and pancreatitis. Patients taking linagliptin should limit alcohol consumption and discuss safe levels of intake with their healthcare provider. Excessive alcohol use is a known risk factor for acute pancreatitis.
Stopping linagliptin suddenly can lead to a 'rebound' increase in blood glucose levels. There is no specific withdrawal syndrome or tapering requirement, but discontinuation should only occur under medical supervision so that alternative glucose-lowering therapies can be initiated if necessary.
> Important: Discuss all your medical conditions and lifestyle habits with your healthcare provider before starting Linagliptin to ensure it is the safest choice for your treatment plan.
Linagliptin is not known to interfere with common laboratory tests. However, it will lower your HbA1c and blood glucose readings, which is the intended therapeutic effect. It may also cause slight elevations in serum lipase or uric acid, which should be interpreted in the clinical context.
Most interactions with linagliptin occur through the P-glycoprotein (P-gp) transporter or the CYP3A4 enzyme system. P-gp is a pump that moves drugs out of cells; inducers of this pump (like rifampin) flush linagliptin out of the body too quickly. Conversely, inhibitors of this pump might increase linagliptin levels, though the clinical impact of this is usually minimal because linagliptin is not primarily cleared by the liver or kidneys.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is the best way to prevent dangerous interactions.
These are conditions where the risks may outweigh the benefits, or where extreme caution is required:
There is a potential for cross-sensitivity between different DPP-4 inhibitors. If a patient has experienced angioedema or a severe rash with sitagliptin, saxagliptin, or alogliptin, there is an increased risk that they will have a similar reaction to linagliptin. Healthcare providers should exercise caution when switching between agents in this class after an allergic event.
> Important: Your healthcare provider will evaluate your complete medical history, including any past allergic reactions to medications, before prescribing Linagliptin. Always disclose any history of abdominal pain or heart issues.
In clinical trials, a large number of patients aged 65 and over were treated with linagliptin. No overall differences in safety or effectiveness were observed between these patients and younger patients. Linagliptin is particularly useful in the elderly because it does not require dose adjustments for declining kidney function, which is common in this age group. However, the risk of hypoglycemia is higher in the elderly if linagliptin is combined with other drugs, so cautious monitoring is advised.
Linagliptin is the only DPP-4 inhibitor that does not require dose adjustment in patients with renal impairment. Whether a patient has mild, moderate, or severe kidney disease, or is on dialysis, the dose remains 5 mg once daily. This makes it a 'first-choice' gliptin for patients with diabetic nephropathy (kidney disease caused by diabetes).
Clinical studies in patients with mild, moderate, and severe hepatic impairment (Child-Pugh classes A, B, and C) showed that linagliptin levels were not significantly affected by liver disease. Therefore, no dose adjustment is necessary for patients with liver issues.
> Important: Special populations require individualized medical assessment. Always inform your specialist (e.g., obstetrician or nephrologist) if you are taking linagliptin.
| Bioavailability | ~30% |
| Protein Binding | 70% to 99% (Concentration-dependent) |
| Half-life | ~12 hours (Effective); >100 hours (Terminal) |
| Tmax | 1.5 hours |
| Metabolism | Minimal (<5%); CYP3A4 (minor) |
| Excretion | Fecal 80%, Renal 5% |
Linagliptin is classified as a Dipeptidyl Peptidase 4 (DPP-4) Inhibitor. It belongs to the 'gliptin' family of medications. Other drugs in this class include sitagliptin (Januvia), saxagliptin (Onglyza), and alogliptin (Nesina). Linagliptin is unique within this class due to its primarily non-renal route of elimination.